 | • レポートコード：TPM-NV212 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、243ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、継続的腎代替療法の世界市場について調べ、継続的腎代替療法の世界市場規模、市場動向、市場シェア、市場環境、市場予測、モード別（低速連続限外ろ過（SCUF）、連続静脈静脈血液ろ過（CVVHF）、連続静脈静脈血液透析（CVVHD）、および連続静脈静脈血液透析（CVVHDF））分析、製品別（透析液＆交換液、使い捨て、およびシステム）分析、療法別（腎、非腎、および併用）分析、エンドユーザー別（病院、診療所、その他）分析、関連企業情報などをまとめました。 ・継続的腎代替療法の市場概要 ・継続的腎代替療法の市場動向 ・継続的腎代替療法の世界市場規模・予測 ・継続的腎代替療法市場：モード別（低速連続限外ろ過（SCUF）、連続静脈静脈血液ろ過（CVVHF）、連続静脈静脈血液透析（CVVHD）、および連続静脈静脈血液透析（CVVHDF）） ・継続的腎代替療法市場：製品別（透析液＆交換液、使い捨て、およびシステム） ・継続的腎代替療法市場：製品別（透析液＆交換液、使い捨て、およびシステム） ・継続的腎代替療法市場：エンドユーザー別（病院、診療所、その他） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Growing incidences of acute kidney injury (AKI) have catalyzed the need for improved and quality treatment therapies in the continuous renal replacement therapy (CRRT) landscape. South East Asia and South America, individually, account for ~31% each, of the hospitalized population suffering from acute kidney injury in 2018. With the help of several clinical trials, continuous venovenous haemodiafiltration (CVVHDF) and the continuous venovenous heamofiltration (CVVHF) mode of therapies have helped improve the survival rates in patients suffering from sepsis-induced acute kidney injury (SAKI).
As such, healthcare providers in hospitals are adopting continuous extracorporeal therapies to cater to the growing need for multi-organ support in critically-ill patients. The introduction of continuous renal replacement therapy has helped healthcare providers safely perform extracorporeal therapies in intensive care units (ICUs) that are less equipped with dialysis infrastructure. New advancements in continuous renal replacement therapy have also helped provide improved medical care to patients with hemodynamic tolerance concerns. Thus, manufacturers should innovate on venovenous systems and modern integrated full-volume pump monitors to help healthcare institutions carry out safe extracorporeal therapies.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Continuous Renal Replacement Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Continuous Renal Replacement Therapy Market Analysis Forecast, 2017–2027
4.4.1. Market Revenue Projection (US$ Mn)
5. Market Outlook
5.1. Incidence of Acute Kidney Injury Across the Globe
5.2. Rise in Prevalence of Diabetes and Hypertension
5.3. Reimbursement Scenario by Region/globally
5.4. Regulatory Scenario by Region/globally
5.5. Recent Technological Developments in Continuous Renal Replacement Therapy
5.6. Development of CRRT System for Paediatric Patients
5.7. Key Mergers & Acquisitions
6. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Mode
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Continuous Renal Replacement Therapy Market Value (US$) Forecast, by Mode, 2017–2027
6.3.1. Slow Continuous Ultrafiltration (SCUF)
6.3.2. Continuous VenoVenous Haemofiltration (CVVHF)
6.3.3. Continuous VenoVenous Haemodialysis (CVVHD)
6.3.4. Continuous VenoVenous Haemodiafiltration (CVVHDF)
6.4. Continuous Renal Replacement Therapy Market Attractiveness, by Mode
7. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
7.3.1. Dialysate & Replacement Fluids
7.3.2. Disposables
7.3.2.1. Bloodline Sets
7.3.2.2. Hemofilters
7.3.2.3. Other Disposables
7.3.3. Systems
7.4. Continuous Renal Replacement Therapy Market Attractiveness, by Product
8. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Therapy
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
8.3.1. Renal
8.3.2. Non-renal
8.3.3. Combination
8.4. Continuous Renal Replacement Therapy Market Attractiveness, by Therapy
9. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Continuous Renal Replacement Therapy Market Attractiveness, by End-user
10. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Region
10.1. Key Findings
10.2. Continuous Renal Replacement Therapy Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Continuous Renal Replacement Therapy Market Attractiveness, by Country/Region
11. North America Continuous Renal Replacement Therapy Market Analysis
11.1. Introduction
11.1.1. Key Findings
11.2. North America Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027
11.2.1. Slow Continuous Ultrafiltration (SCUF)
11.2.2. Continuous Venovenous Haemofiltration (CVVHF)
11.2.3. Continuous Venovenous Haemodialysis (CVVHD)
11.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)
11.3. North America Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
11.3.1. Dialysate & Replacement Fluids
11.3.2. Disposables
11.3.2.1. Bloodline Sets
11.3.2.2. Hemofilters
11.3.2.3. Other Disposables
11.3.3. Systems
11.4. North America Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
11.4.1. Renal
11.4.2. Non-renal
11.4.3. Combination
11.5. North America Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Others
11.6. North America Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Continuous Renal Replacement Therapy Market Attractiveness Analysis
11.7.1. By Mode
11.7.2. By Product
11.7.3. By Therapy
11.7.4. By End-user
11.7.5. By Country
12. Europe Continuous Renal Replacement Therapy Market Analysis
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027
12.2.1. Slow Continuous Ultrafiltration (SCUF)
12.2.2. Continuous Venovenous Haemofiltration (CVVHF)
12.2.3. Continuous Venovenous Haemodialysis (CVVHD)
12.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)
12.3. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
12.3.1. Dialysate & Replacement Fluids
12.3.2. Disposables
12.3.2.1. Bloodline Sets
12.3.2.2. Hemofilters
12.3.2.3. Other Disposables
12.3.3. Systems
12.4. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
12.4.1. Renal
12.4.2. Non-renal
12.4.3. Combination
12.5. Europe Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Others
12.6. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis
12.7.1. By Mode
12.7.2. By Product
12.7.3. By Therapy
12.7.4. By End-user
12.7.5. By Country
13. Asia-Pacific Continuous Renal Replacement Therapy Market Analysis
13.1. Introduction
13.1.1. Key Findings
13.2. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027
13.2.1. Slow Continuous Ultrafiltration (SCUF)
13.2.2. Continuous Venovenous Haemofiltration (CVVHF)
13.2.3. Continuous Venovenous Haemodialysis (CVVHD)
13.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)
13.3. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
13.3.1. Dialysate & Replacement Fluids
13.3.2. Disposables
13.3.2.1. Bloodline Sets
13.3.2.2. Hemofilters
13.3.2.3. Other Disposables
13.3.3. Systems
13.4. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
13.4.1. Renal
13.4.2. Non-renal
13.4.3. Combination
13.5. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Others
13.6. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia-Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis
13.7.1. By Mode
13.7.2. By Product
13.7.3. By Therapy
13.7.4. By End-user
13.7.5. By Country
14. Latin America Continuous Renal Replacement Therapy Market Analysis
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027
14.2.1. Slow Continuous Ultrafiltration (SCUF)
14.2.2. Continuous Venovenous Haemofiltration (CVVHF)
14.2.3. Continuous Venovenous Haemodialysis (CVVHD)
14.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)
14.3. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
14.3.1. Dialysate & Replacement Fluids
14.3.2. Disposables
14.3.2.1. Bloodline Sets
14.3.2.2. Hemofilters
14.3.2.3. Other Disposables
14.3.3. Systems
14.4. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
14.4.1. Renal
14.4.2. Non-renal
14.4.3. Combination
14.5. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Others
14.6. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis
14.7.1. By Mode
14.7.2. By Product
14.7.3. By Therapy
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027
15.2.1. Slow Continuous Ultrafiltration (SCUF)
15.2.2. Continuous Venovenous Haemofiltration (CVVHF)
15.2.3. Continuous Venovenous Haemodialysis (CVVHD)
15.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)
15.3. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027
15.3.1. Dialysate & Replacement Fluids
15.3.2. Disposables
15.3.2.1. Bloodline Sets
15.3.2.2. Hemofilters
15.3.2.3. Other Disposables
15.3.3. Systems
15.4. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027
15.4.1. Renal
15.4.2. Non-renal
15.4.3. Combination
15.5. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Others
15.6. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis
15.7.1. By Mode
15.7.2. By Product
15.7.3. By Therapy
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Position By Company (2018)
16.3. Company Profiles
16.3.1. Baxter International, Inc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Strategic Overview
16.3.1.5. SWOT Analysis
16.3.2. Nipro Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Strategic Overview
16.3.2.5. SWOT Analysis
16.3.3. Fresenius Medical Care AG & Co. KGaA
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Strategic Overview
16.3.3.5. SWOT Analysis
16.3.4. Asahi Kasei Corporation
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Strategic Overview
16.3.4.5. SWOT Analysis
16.3.5. B. Braun Melsungen AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Strategic Overview
16.3.5.5. SWOT Analysis
16.3.6. NIKKISO CO., LTD
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Strategic Overview
16.3.6.5. SWOT Analysis
16.3.7. Medica SPA
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Strategic Overview
16.3.7.4. SWOT Analysis
16.3.8. INFOMED SA
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Strategic Overview
16.3.8.4. SWOT Analysis
16.3.9. Medtronic (Bellco Società unipersonale a r.l.)
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Strategic Overview
16.3.9.5. SWOT Analysis
16.3.10. Toray Medical Company Limited (Toray Industries, Inc.)
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Strategic Overview
16.3.10.4. SWOT Analysis